Cullinan Therapeutics (CGEM) Non-Current Assets (2020 - 2026)

Cullinan Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $41.6 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 84.13% year-over-year to $41.6 million in Q1 2026; TTM through Mar 2026 was $489.5 million, a 8.28% decrease from a year earlier, with the FY2025 full-year figure at $61.6 million, down 70.26% from the prior year.
• Non-Current Assets fell to $41.6 million in Q1 2026 per CGEM's latest filing, from $61.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $261.9 million in Q1 2025 and bottomed at $3.4 million in Q2 2024.
• The 5-year median for Non-Current Assets is $61.2 million (2024), against an average of $86.5 million.
• Across the five-year window, Non-Current Assets plunged 96.8% in 2024 and soared 7053.0% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $86.6 million in 2022, then sank by 95.39% to $4.0 million in 2023, then soared by 5090.58% to $207.2 million in 2024, then slumped by 70.26% to $61.6 million in 2025, then tumbled by 32.52% to $41.6 million in 2026.
• Per Business Quant, the three latest CGEM Non-Current Assets figures stand at $41.6 million (Q1 2026), $61.6 million (Q4 2025), and $141.9 million (Q3 2025).